{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the time point for assessment","groupId":"OG000","lowerLimit":"8.100","upperLimit":"NA","value":"19.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"From the first dose until the data cut-off date of 03 September 2014; maximum time on treatment was 36.0 weeks","title":"Kaplan-Meier Estimates of Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}